Bionor Pharma Announces that the Combination of Vacc-4x + Revlimid® is Well Tolerated and Increases CD4 Counts in People Living with HIV

(Oslo, Norway, 17 November 2014) Bionor Pharma ASA (OSE:BIONOR) announces the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the “Boost & Kill” study. The Phase II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid versus Vacc-4x in HIV subjects on ART (HIV standard of care treatment). …

Read more

Bionor Pharma’s REDUC trial – Highlight of the 2014 AIDS conference

At the 2014 AIDS conference in Melbourne the results from Part A for Bionor Pharma’s REDUC trial was one of the key events and a substantial media coverage followed the presentation of the data. The trial combines Bionor Pharma’s therapeutic vaccine candidate Vacc-4x with the cancer drug Romidepsin (Celgene Corp) and is conducted in collaboration …

Read more

First Evidence that Romidepsin “Kicks” HIV out of Reservoirs

Results from Part A of Bionor Pharma’s REDUC study Presented at the 2014 AIDS Conference and IAS’ HIV Cure Symposium (Oslo, Norway, 22 July 2014)  Bionor Pharma ASA (OSE: BIONOR) announces that data from part A of the REDUC study has been presented at the 2014 International AIDS Conference in Melbourne, Australia. The topline results …

Read more